Patents by Inventor Mitchell F. Brin

Mitchell F. Brin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9078892
    Abstract: An acute pain medication overuse disorder (such as a medication overuse headache disorder) can be treated by administration of a botulinum toxin to a patient. The botulinum toxin can be botulinum toxin type A and the botulinum toxin can be administered to or to the vicinity of where a patient experiences or is predisposed to experience pain or a headache.
    Type: Grant
    Filed: February 26, 2004
    Date of Patent: July 14, 2015
    Assignee: Allergan, Inc.
    Inventors: Catherine C. Turkel, Mitchell F. Brin
  • Patent number: 9078893
    Abstract: A headache can be treated effectively by administration of a botulinum toxin to a patient at specific muscles using specific doses.
    Type: Grant
    Filed: October 23, 2008
    Date of Patent: July 14, 2015
    Assignee: Allergan, Inc.
    Inventors: Catherine C. Turkel, Mitchell F. Brin
  • Patent number: 9061025
    Abstract: A method for treating a headache by selecting a patient determined to be responsive to administration of a botulinum neurotoxin for treatment of a headache by determining that the patient has or has a propensity to have an imploding headache and/or an ocular headache pain and administering a botulinum toxin to the patient, thereby treating the headache. A method for selecting from a population of patients with headache or with a propensity to have a headache, those patients whose headache will respond to administration of a botulinum neurotoxin by identifying from a population of patients with headache or with a propensity to have a headache those patients who have or who have a propensity to have an imploding headache pain and/or an ocular headache pain.
    Type: Grant
    Filed: August 31, 2006
    Date of Patent: June 23, 2015
    Assignee: Allergan, Inc.
    Inventors: Rami Burstein, Catherine C. Turkel, Mitchell F. Brin
  • Patent number: 8968747
    Abstract: Disorders such as headaches can be treated by administration of a botulinum toxin to a patient suffering therefrom, such as a migraine headache. A combined a fixed site/fixed dose and an optional follow the pain variable dosage and injection site paradigm is disclosed for optimizing clinical effectiveness of botulinum toxin administration for patients suffering headache, particularly chronic migraine.
    Type: Grant
    Filed: April 16, 2013
    Date of Patent: March 3, 2015
    Assignee: Allergan, Inc.
    Inventors: Catherine C. Turkel, Sheena K. Aurora, Mitchell F. Brin
  • Patent number: 8940308
    Abstract: Disclosed is a method for decreasing depression in a patient by local administration of a botulinum neurotoxin to the frontalis, corrugator, procereus, occipitalis, temporalis, trapezius and cervical paraspinal muscles.
    Type: Grant
    Filed: February 1, 2013
    Date of Patent: January 27, 2015
    Assignee: Allergan, Inc.
    Inventors: Catherine C. Turkel, Mitchell F. Brin
  • Patent number: 8936790
    Abstract: Disorders such as headaches can be treated by administration of a botulinum toxin to a patient suffering therefrom, such as a migraine headache. A combined a fixed site/fixed dose and an optional follow the pain variable dosage and injection site paradigm is disclosed for optimizing clinical effectiveness of botulinum toxin administration for patients suffering headache, particularly chronic migraine.
    Type: Grant
    Filed: April 16, 2013
    Date of Patent: January 20, 2015
    Assignee: Allergan, Inc.
    Inventors: Catherine C. Turkel, Sheena K. Aurora, Mitchell F. Brin
  • Patent number: 8889151
    Abstract: A headache can be treated more effectively by co-administration of a botulinum toxin and a triptan drug to a patient and/or the effectiveness of a triptan medication can be increased. The botulinum toxin can be botulinum toxin type A and the botulinum toxin can be administered to or to the vicinity of where a patient experiences or is predisposed to experience pain or a headache.
    Type: Grant
    Filed: March 19, 2010
    Date of Patent: November 18, 2014
    Assignee: Allergan, Inc.
    Inventors: Catherine C. Turkel, Mitchell F. Brin
  • Publication number: 20140294803
    Abstract: A headache can be treated more effectively by co-administration of a botulinum toxin and a triptan drug to a patient and/or the effectiveness of a triptan medication can be increased. The botulinum toxin can be botulinum toxin type A and the botulinum toxin can be administered to or to the vicinity of where a patient experiences or is predisposed to experience pain or a headache.
    Type: Application
    Filed: March 26, 2014
    Publication date: October 2, 2014
    Applicant: ALLERGAN, INC.
    Inventors: Catherine C. Turkel, Mitchell F. Brin
  • Publication number: 20140170132
    Abstract: The present invention relates to methods for prophylactic treatment of Herpes recurrence with a Clostridial neurotoxin, such as a botulinum neurotoxin or variant thereof.
    Type: Application
    Filed: December 17, 2013
    Publication date: June 19, 2014
    Applicant: Allergan, Inc.
    Inventor: Mitchell F. Brin
  • Publication number: 20140030248
    Abstract: Disorders such as headaches can be treated by administration of a botulinum toxin to a patient suffering therefrom, such as a migraine headache. A combined a fixed site/fixed dose and an optional follow the pain variable dosage and injection site paradigm is disclosed for optimizing clinical effectiveness of botulinum toxin administration for patients suffering headache, particularly chronic migraine.
    Type: Application
    Filed: April 16, 2013
    Publication date: January 30, 2014
    Applicant: Allergan, Inc.
    Inventors: Catherine C. Turkel, Sheena K. Aurora, Mitchell F. Brin
  • Patent number: 8609112
    Abstract: Methods for preventing or treating depression including a depression mediated by the thalamus. Depression, including a thalamically mediated depression, can be treated by peripheral administration of a botulinum toxin to or to the vicinity of a trigeminal sensory nerve, thereby preventing or treating the depression.
    Type: Grant
    Filed: February 1, 2013
    Date of Patent: December 17, 2013
    Assignee: Allergan, Inc.
    Inventors: Andrew M. Blumenfeld, Catherine C. Turkel, Mitchell F. Brin
  • Patent number: 8609113
    Abstract: Methods for preventing or treating depression including a depression mediated by the thalamus. Depression, including a thalamically mediated depression, can be treated by peripheral administration of a botulinum toxin to or to the vicinity of a trigeminal sensory nerve, thereby preventing or treating the depression.
    Type: Grant
    Filed: February 1, 2013
    Date of Patent: December 17, 2013
    Assignee: Allergan, Inc.
    Inventors: Andrew M. Blumenfeld, Catherine C. Turkel, Mitchell F. Brin
  • Publication number: 20130251830
    Abstract: Methods for treating a coronary risk factor (such as hypertension, diabetes, hyperlipidemia and obesity) and/or a respiratory disorder (such as asthma, chronic obstructive pulmonary disease and bronchitis) and/or arthritis by local administration of a botulinum neurotoxin to at least one of a head, neck or shoulder location (for example, by subdermal, subcutaneous or intramuscular administration of the botulinum neurotoxin) of a patient with a coronary risk factor, respiratory disorder or arthritis.
    Type: Application
    Filed: May 22, 2013
    Publication date: September 26, 2013
    Applicant: Allergan, Inc.
    Inventors: Aubrey N. Manack, Mitchell F. Brin
  • Patent number: 8501195
    Abstract: Disorders such as headaches can be treated by administration of a botulinum toxin to a patient suffering therefrom, such as a migraine headache. A combined a fixed site/fixed dose and an optional follow the pain variable dosage and injection site paradigm is disclosed for optimizing clinical effectiveness of botulinum toxin administration for patients suffering headache, particularly chronic migraine.
    Type: Grant
    Filed: March 30, 2011
    Date of Patent: August 6, 2013
    Assignee: Allergan, Inc.
    Inventors: Catherine C. Turkel, Mitchell F. Brin, Sheena K. Aurora, David W. Dodick
  • Patent number: 8470337
    Abstract: Methods for treating a coronary risk factor (such as hypertension, diabetes, hyperlipidemia and obesity) and/or a respiratory disorder (such as asthma, chronic obstructive pulmonary disease and bronchitis) and/or arthritis by local administration of a botulinum neurotoxin to at least one of a head, neck or shoulder location (for example, by subdermal, subcutaneous or intramuscular administration of the botulinum neurotoxin) of a patient with a coronary risk factor, respiratory disorder or arthritis.
    Type: Grant
    Filed: March 13, 2008
    Date of Patent: June 25, 2013
    Assignee: Allergan, Inc.
    Inventors: Aubrey N. Manack, Mitchell F. Brin
  • Publication number: 20130034587
    Abstract: The invention provides compositions and methods for treating incontinence associated with sexual activity.
    Type: Application
    Filed: July 13, 2012
    Publication date: February 7, 2013
    Applicant: ALLERGAN, INC.
    Inventor: Mitchell F. BRIN
  • Publication number: 20120302574
    Abstract: The present invention provides a method of preventing or reducing the severity of a stress-associated condition in a subject by systemically administering to the subject an effective amount of brimonidine or a pharmaceutically acceptable salt, ester, amide, sterioisomer or racemic mixture thereof. Stress-associated conditions that can be treated according to a method of the invention include, but are not limited to, dyspepsia, tachycardias other than tachycardia associated with myocardial ischemia, panic attack, non-inflammatory dermatogical conditions, disorders of muscle contraction, sensory hypersensitivity associated with migraine, and behavioral disorders.
    Type: Application
    Filed: June 1, 2012
    Publication date: November 29, 2012
    Applicant: ALLERGAN, INC.
    Inventors: Daniel W. Gil, Scott Whitcup, Mitchell F. Brin, John E. Donello
  • Publication number: 20120258132
    Abstract: The present specification discloses TEMs, compositions comprising such TEMs, compositions comprising such TEMs and Clostridial toxins, methods of treating a vagal nerve-based disorder in an individual using such compositions, use of such TEMs in manufacturing a medicament for treating a vagal nerve-based disorder, use of such TEMs and Clostridial toxins in manufacturing a medicament for treating a vagal nerve-based disorder, use of such TEMs in treating a vagal nerve-based disorder, and use of such TEMs and Clostridial toxins in treating a vagal nerve-based disorder.
    Type: Application
    Filed: March 28, 2012
    Publication date: October 11, 2012
    Applicant: ALLERGAN, INC.
    Inventors: Andrew M. BLUMENFELD, Mitchell F. Brin
  • Publication number: 20120251518
    Abstract: The present specification discloses TEMs, compositions comprising such TEMs, compositions comprising such TEMs and Clostridial toxins, methods of treating a sexual dysfunction disorder in an individual using such compositions, use of such TEMs in manufacturing a medicament for treating a sexual dysfunction disorder, use of such TEMs and Clostridial toxins in manufacturing a medicament for treating a sexual dysfunction disorder, use of such TEMs in treating a sexual dysfunction disorder, and use of such TEMs and Clostridial toxins in treating a sexual dysfunction disorder.
    Type: Application
    Filed: March 20, 2012
    Publication date: October 4, 2012
    Applicant: ALLERGAN, INC.
    Inventors: Andrew M. Blumenfeld, Mitchell F. Brin
  • Publication number: 20120251574
    Abstract: The present specification discloses Clostridial neurotoxins and TEMs, compositions comprising such Clostridial neurotoxins and TEMs, methods of treating a multiple medical disorder in an individual using such compositions, use of such Clostridial neurotoxins and TEMs in manufacturing a medicament for treating a multiple medical disorder, and uses of such Clostridial neurotoxins and TEMs in treating a multiple medical disorder.
    Type: Application
    Filed: March 20, 2012
    Publication date: October 4, 2012
    Applicant: ALLERGAN, INC.
    Inventors: Andrew M. Blumenfeld, Mitchell F. Brin